×
About 3,216 results

ALLMedicine™ Primary Myelofibrosis Center

Research & Reviews  1,585 results

New germline GATA1 variant in females with anemia and thrombocytopenia.
https://doi.org/10.1016/j.bcmd.2021.102545
Blood Cells, Molecules & Diseases; Svidnicki MCCM, Filho MAF et. al.

Feb 21st, 2021 - Familial forms of bone marrow defects are rare disorders and description of new cases are valuable opportunities to clarify the molecular machinery that triggers hematopoiesis and blood formation, as well as risk to malignant transformation. We in...

A systematic review of antithrombotic treatment of venous thromboembolism in patients w...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805324
Blood Advances; Hamulyák EN, Daams JG et. al.

Feb 11th, 2021 - Patients with myeloproliferative neoplasms (MPNs), polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have an increased risk of thrombosis. Risk of recurrent thrombosis can be reduced with antithrombotic therapy and/or cytore...

A patient with a germline GATA2 mutation and primary myelofibrosis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876883
Blood Advances; Rütsche CV, Haralambieva E et. al.

Feb 9th, 2021 - A patient with a germline GATA2 mutation and primary myelofibrosis.|2021|Rütsche CV,Haralambieva E,Lysenko V,Balabanov S,Theocharides APA,|

Genome-wide DNA methylation profiling is able to identify prefibrotic PMF cases at risk...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860011
Clinical Epigenetics; Lehmann U, Stark H et. al.

Feb 5th, 2021 - Patients suffering from the BCR-ABL1-negative myeloproliferative disease prefibrotic primary myelofibrosis (pre-PMF) have a certain risk for progression to myelofibrosis. Accurate risk estimation for this fibrotic progression is of prognostic impo...

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell tr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133490
Pediatrics in Review; Rondelli D, Goldberg JD et. al.

Feb 2nd, 2021 - From 2007 to 2011, 66 patients with primary myelofibrosis or myelofibrosis (MF) preceded by essential thrombocythemia or polycythemia vera were enrolled into a prospective phase 2 clinical trial of reduced-intensity allogeneic hematopoietic stem c...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  1,607 results

New germline GATA1 variant in females with anemia and thrombocytopenia.
https://doi.org/10.1016/j.bcmd.2021.102545
Blood Cells, Molecules & Diseases; Svidnicki MCCM, Filho MAF et. al.

Feb 21st, 2021 - Familial forms of bone marrow defects are rare disorders and description of new cases are valuable opportunities to clarify the molecular machinery that triggers hematopoiesis and blood formation, as well as risk to malignant transformation. We in...

A systematic review of antithrombotic treatment of venous thromboembolism in patients w...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805324
Blood Advances; Hamulyák EN, Daams JG et. al.

Feb 11th, 2021 - Patients with myeloproliferative neoplasms (MPNs), polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have an increased risk of thrombosis. Risk of recurrent thrombosis can be reduced with antithrombotic therapy and/or cytore...

A patient with a germline GATA2 mutation and primary myelofibrosis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876883
Blood Advances; Rütsche CV, Haralambieva E et. al.

Feb 9th, 2021 - A patient with a germline GATA2 mutation and primary myelofibrosis.|2021|Rütsche CV,Haralambieva E,Lysenko V,Balabanov S,Theocharides APA,|

Genome-wide DNA methylation profiling is able to identify prefibrotic PMF cases at risk...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860011
Clinical Epigenetics; Lehmann U, Stark H et. al.

Feb 5th, 2021 - Patients suffering from the BCR-ABL1-negative myeloproliferative disease prefibrotic primary myelofibrosis (pre-PMF) have a certain risk for progression to myelofibrosis. Accurate risk estimation for this fibrotic progression is of prognostic impo...

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell tr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133490
Pediatrics in Review; Rondelli D, Goldberg JD et. al.

Feb 2nd, 2021 - From 2007 to 2011, 66 patients with primary myelofibrosis or myelofibrosis (MF) preceded by essential thrombocythemia or polycythemia vera were enrolled into a prospective phase 2 clinical trial of reduced-intensity allogeneic hematopoietic stem c...

see more →

News  23 results

Fast Five Quiz: Prognosis of Primary Myelofibrosis
https://reference.medscape.com/viewarticle/933699_2

Jul 15th, 2020 - Figure 1. Enlarged spleen (splenomegaly). Light micrograph of a section through an enlarged spleen that has occurred in myelofibrosis. PMF is an uncommon disease, with an annual incidence of approximately 0.5-1.5 cases per 100,000 individuals in t...

Fast Five Quiz: Prognosis of Primary Myelofibrosis
https://reference.medscape.com/viewarticle/933699_1

Jul 15th, 2020 - Formerly known as "agnogenic myeloid metaplasia," primary myelofibrosis (PMF) is a bone marrow and blood cancer in which a clonal disorder arises from the neoplastic transformation of early hematopoietic stem cells. One of a heterogeneous group of...

Fast Five Quiz: Prognosis of Primary Myelofibrosis
https://reference.medscape.com/viewarticle/933699

Jul 15th, 2020 - Formerly known as "agnogenic myeloid metaplasia," primary myelofibrosis (PMF) is a bone marrow and blood cancer in which a clonal disorder arises from the neoplastic transformation of early hematopoietic stem cells. One of a heterogeneous group of...

Fast Five Quiz: Prognosis of Primary Myelofibrosis
https://reference.medscape.com/viewarticle/933699_4

Jul 15th, 2020 - A Mayo-Careggi MPN Alliance study found that among 709 Mayo Clinic patients with PMF, 66% had a JAK2 mutation, 19% had a CALR mutation, and 5.4% had an MPL mutation. A further 10% of patients were triple-negative for these mutations. Patients with...

New JAK2 Inhibitor Approved for Myelofibrosis
https://www.medpagetoday.com/hematologyoncology/hematology/81650

Aug 16th, 2019 - WASHINGTON -- The FDA approved the Janus kinase 2 (JAK2) inhibitor fedratinib (Inrebic) on Friday for adults with the rare bone marrow disease myelofibrosis. Support for the approval came largely from the phase III JAKARTA study, a randomized thre...

see more →